Cart
0

Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_182593
Pages: 196
Jan 2018 | 4162 Views
 
Author's : Tenzin Kunsel and Onkar Sumant
Tables: 80
Charts: 47
 

Antidepressant Drugs Market Overview:

Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression. According to WHO almost 350 million people worldwide were affected with depression in 2016. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression. The global antidepressant drugs market was valued at $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023.

Increase in prevalence of depression, rise in geriatric population, and emergence of novel techniques for the development of drugs with fewer side-effects drive the market. Moreover, increase in awareness regarding the disease state and required clinical needs, and rise in number of people suffering from stress can fuel the growth of the antidepressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

Depressive Disorder Segment Review

Based on depressive disorder, it is categorized into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. Major depressive disorder is the largest contributor toward the market growth as majority of the people are usually diagnosed with this disorder due to increase in stress levels. However, obsessive-compulsive disorder is the fastest growing segment.

Get more information on this report : Request Sample Pages

Product Segment Review

Based on product, it is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others. Selective serotonin reuptake inhibitors is the dominant segment owing to the presence of large number of these drugs.

Get more information on this report : Request Sample Pages

Global Antidepressant Drugs Market: Key Geographic Segment

Based on region, the antidepressant drugs market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the antidepressant drugs market in 2016, and is expected to retain its dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

The key players operating in the global antidepressant drugs market include Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Other prominent players in the value chain include Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories, and AstraZeneca.

Key Benefits for Stakeholders

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Antidepressant Drugs Market Key Segments:

By Depression Disorder

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Product

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine reuptake Inhibitors
  • Monoamine oxidase inhibitors
  • Serotonin antagonist and reuptake inhibitors
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis
3.4. Porter’s five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Increase in prevalence of depression
3.5.1.2. Rise in geriatric population
3.5.1.3. Increase in awareness towards depression

3.5.2. Restraints

3.5.2.1. Preference of non-pharmacological therapies over pharmacological therapies
3.5.2.2. Poor efficacy & safety profiles
3.5.2.3. Patent expiry of antidepressants leading to weak pipeline

3.5.3. Opportunity

3.5.3.1. Emergence of novel multimodal therapies

Chapter: 4: ANTIDEPRESSANT DRUGS MARKET, BY DEPRESSIVE DISORDER

4.1. Overview

4.1.1. Market size and forecast

4.2. Major depressive disorder

4.2.1. Key market trends & opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.2.4. Postpartum depressive disorder

4.2.4.1. Global market size and forecast for postpartum depression disorder drugs

4.2.5. U.S. postpartum depressive disorder

4.2.5.1. U.S. market size and forecast for postpartum depression disorder drugs

4.2.6. Market share analysis postpartum depressive disorder

4.3. Obsessive–compulsive disorder

4.3.1. Key market trends & opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Generalized anxiety disorder

4.4.1. Key market trends & opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

4.5. Panic disorder

4.5.1. Key market trends & opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

4.6. Others

4.6.1. Key market trends & opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country

Chapter: 5: ANTIDEPRESSANT DRUGS MARKET, BY PRODUCT

5.1. Overview

5.1.1. Market size and forecast

5.2. Tricyclic antidepressants

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Selective serotonin reuptake inhibitors

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Serotonin–norepinephrine reuptake inhibitors

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Monoamine oxidase inhibitors

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Serotonin antagonist & reuptake inhibitors

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

5.7. Others

5.7.1. Market size and forecast
5.7.2. Market analysis, by country

Chapter: 6: ANTIDEPRESSANT DRUGS MARKET, BY GEOGRAPHY

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends & opportunities
6.2.2. Market size and forecast, by depressive disorder
6.2.3. Market size and forecast, by product
6.2.4. Market size and forecast, by country

6.2.4.1. U.S. market size and forecast, by depressive disorder
6.2.4.2. U.S. market size and forecast, by product
6.2.4.3. Canada market size and forecast, by depressive disorder
6.2.4.4. Canada market size and forecast, by product
6.2.4.5. Mexico market size and forecast, by depressive disorder
6.2.4.6. Mexico market size and forecast, by product

6.3. Europe

6.3.1. Key market trends & opportunities
6.3.2. Market size and forecast, by depressive disorder
6.3.3. Market size and forecast, by product
6.3.4. Market size and forecast, by country

6.3.4.1. Germany market size and forecast, by depressive disorder
6.3.4.2. Germany market size and forecast, by product
6.3.4.3. France market size and forecast, by depressive disorder
6.3.4.4. France market size and forecast, by product
6.3.4.5. UK market size and forecast, by depressive disorder
6.3.4.6. UK market size and forecast, by product
6.3.4.7. Italy market size and forecast, by depressive disorder
6.3.4.8. Italy market size and forecast, by product
6.3.4.9. Spain market size and forecast, by depressive disorder
6.3.4.10. Spain market size and forecast, by product
6.3.4.11. Rest of Europe market size and forecast, by depressive disorder
6.3.4.12. Rest of Europe market size and forecast, by product

6.4. Asia-Pacific

6.4.1. Key market trends & opportunities
6.4.2. Market size and forecast, by depressive disorder
6.4.3. Market size and forecast, by product
6.4.4. Market size and forecast, by country

6.4.4.1. Japan market size and forecast, by depressive disorder
6.4.4.2. Japan market size and forecast, by product
6.4.4.3. China market size and forecast, by depressive disorder
6.4.4.4. China market size and forecast, by product
6.4.4.5. Australia market size and forecast, by depressive disorder
6.4.4.6. Australia market size and forecast, by product
6.4.4.7. India market size and forecast, by depressive disorder
6.4.4.8. India market size and forecast, by product
6.4.4.9. South Korea market size and forecast, by depressive disorder
6.4.4.10. South Korea market size and forecast, by product
6.4.4.11. Rest of Asia-Pacific market size and forecast, by depressive disorder
6.4.4.12. Rest of Asia-Pacific market size and forecast, by product

6.5. LAMEA

6.5.1. Key market trends & opportunities
6.5.2. Market size and forecast, by depressive disorder
6.5.3. Market size and forecast, by product
6.5.4. Market size and forecast, by country

6.5.4.1. Brazil market size and forecast, by depressive disorder
6.5.4.2. Brazil market size and forecast, by product
6.5.4.3. Saudi Arabia market size and forecast, by depressive disorder
6.5.4.4. Saudi Arabia market size and forecast, by product
6.5.4.5. South Africa market size and forecast, by depressive disorder
6.5.4.6. South Africa market size and forecast, by product
6.5.4.7. Rest of LAMEA market size and forecast, by depressive disorder
6.5.4.8. Rest of LAMEA market size and forecast, by product

Chapter: 7: COMPANY PROFILES

7.1. Alkermes Plc

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance

7.2. Allergan Plc

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. Bristol Myers Squibb Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Business performance

7.4. Eli Lilly and Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance

7.5. GlaxoSmithKline Inc.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance

7.6. H. Lundbeck A/S

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Business performance
7.6.4. Key strategic moves and developments

7.7. Merck Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance

7.8. Pfizer Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance

7.9. Teva Pharmaceutical Industries Ltd.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance

7.10. Takeda Pharmaceutical Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 02. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 03. ANTIDEPRESSANTS DRUGS FOR POSTPARTUN DEPRESSION WITH RESPECTIVE MANUFACTURERS
TABLE 04. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OBSESSIVE–COMPULSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 06. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR PANIC DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OTHER DEPRESSIVE DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 08. GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 09. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS,  BY REGION, 2016-2023 ($MILLION)
TABLE 12. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN ANTAGONIST & REUPTAKE INHIBITORS,  BY REGION, 2016-2023 ($MILLION)
TABLE 14. ANTIDEPRESSANT DRUGS MARKET REVENUE FOR OTHERS, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 15. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. U.S. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 20. U.S. ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 21. CANADA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 22. CANADA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 23. MEXICO ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 24. MEXICO ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 25. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 26. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 27. EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28. GERMANY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 29. GERMANY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 30. FRANCE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 31. FRANCE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 32. UK ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 33. UK ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 34. ITALY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 35. ITALY ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 36. SPAIN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 37. SPAIN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. REST OF EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 39. REST OF EUROPE ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 41. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 43. JAPAN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 44. JAPAN ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 45. CHINA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 46. CHINA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 47. AUSTRALIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 48. AUSTRALIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 49. INDIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 50. INDIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 52. SOUTH KOREA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 57. LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 58. BRAZIL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 59. BRAZIL ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 61. SAUDI ARABIA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 63. SOUTH AFRICA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 65. REST OF LAMEA ANTIDEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 66. ALKERMES: COMPANY SNAPSHOT
TABLE 67. ALLERGAN: COMPANY SNAPSHOT
TABLE 68. ALLERGAN: OPERATING SEGMENTS
TABLE 69. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 70. LILLY: COMPANY SNAPSHOT
TABLE 71. LILLY: OPERATING SEGMENTS
TABLE 72. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 73. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 74. LUNDBECK: COMPANY SNAPSHOT
TABLE 75. MERCK: COMPANY SNAPSHOT
TABLE 76. MERCK: OPERATING SEGMENTS
TABLE 77. PFIZER: COMPANY SNAPSHOT
TABLE 78. PFIZER: OPERATING SEGMENTS
TABLE 79. SAGE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 80. TEVA: OPERATING SEGMENTS
TABLE 81. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 01. GLOBAL ANTIDEPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2016
FIGURE 04. BARGAINING POWER OF BUYERS
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. HREAT OF NEW ENTRANTS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 10. GLOBAL POSTPARTUM DEPRESSION DISORDER DRUGS MARKET REVENUE, 2016-2023 ($MILLION)
FIGURE 11. U.S. POSTPARTUM DEPRESSION DISORDER DRUGS MARKET REVENUE, 2016-2023 ($MILLION)
FIGURE 12. MARKET SHARE ANALYSIS FOR POSTPARTUM DEPRESSION DISORDER, 2017
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE–COMPULSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OTHER DEPRESSIVE DISORDERS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST & REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY,  2016 & 2023 (%)
FIGURE 23. ALKERMES: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ALKERMES: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. BRISTOL MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. BRISTOL MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. GLAXOSMITHKLINE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. LUNDBECK: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. LUNDBECK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 42. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. TAKEDA PHARMACEUTICAL: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

The advancements regarding development of latest molecules and emergence of novel therapies such as multi-modal therapy are expected to boost the market growth. Such novel therapies have shown positive results for the treatment of depression during clinical studies and cause fewer side-effects. The discovery of new potential medications for the patients suffering from depression has increased over the years. According to American Psychiatric Association antidepressant drugs are one of the most commonly used drug classes in the U.S., and the uptake of the same has increased among the youth in the recent years.

The key factors that have propelled the market growth include the increase in prevalence of depression, along with the increase in geriatric population across the globe. In addition, emergence of novel techniques for the development of drugs with fewer side-effects is expected to boost the market growth. Moreover, increase in awareness regarding the disease as well as required clinical needs, and rise in number of people suffering from stress is expected to fuel the growth of the antidepressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, along with increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

The use of antidepressants is the highest in North America, particularly in the U.S., owing to the high prevalence rate of depression, increase in disposable income among customers, and emergence of novel therapies that cause fewer side-effects. Although the use of gene therapy in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, rise in incidence rate of depression, and large number of geriatric population, which are projected to fuel the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Antidepressant Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4565
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5160
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $6747
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo